Loading
SPEN (Msx2-interacting protein) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer, Non-Hodgkin lymphoma, Renal cell carcinoma and 5 more.
May serve as a nuclear matrix platform that organises and integrates transcriptional responses. In osteoblasts, supports transcription activation: synergises with RUNX2 to enhance FGFR2-mediated activation of the osteocalcin FGF-responsive element (OCFRE). Has also been shown to be an essential corepressor protein, which probably regulates different key pathways such as the Notch pathway.
CIViC holds 1 clinical evidence item and 0 assertions across 1 variant. Open Targets scores its association with cancer at 0.73 (direct and indirect evidence; datatypes literature 0.89, genetic association 0.21, somatic mutation 0.86). IntOGen calls it a driver in 20 cohorts (1 activating, 18 loss-of-function), covering Acute Myeloid Leukaemia, Invasive Breast Carcinoma, Renal Clear Cell Carcinoma, Cervical Squamous Cell Carcinoma, Chronic Lymphocytic Leukaemia/Small Lymphocytic Lymphoma, Diffuse Large B-Cell Lymphoma, NOS and others.
In plain words · SPEN (Msx2-interacting protein) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer, Non-Hodgkin lymphoma, Renal cell carcinoma and 5 more.
SPEN (Msx2-interacting protein) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer, Non-Hodgkin lymphoma, Renal cell carcinoma and 5 more.
May serve as a nuclear matrix platform that organises and integrates transcriptional responses.
No product in this corpus aims at SPEN yet. Transcription factors have no pocket to plug, so drugs either degrade them or block the partner protein they need to dock on DNA.
Tumour-specific alteration: the catalogues call it an oncogene driver (IntOGen cohort analysis finds it activated more often than chance) and a tumour suppressor (IntOGen finds it knocked out more often than chance), so the direction differs between cohorts but the alteration is somatic either way; what a medicine would aim at or exploit is the altered form or its loss, absent from normal cells; no corpus medicine is aimed at it yet. HPA SPEN: RNA low tissue specificity; high antibody staining in 32 normal tissues; highest cancer staining carcinoid (4 of 4 high). Distribution: 8 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Breast cancer (all types), Lymphoma, Renal cell carcinoma, Cervical cancer, Nasopharyngeal carcinoma, Prostate cancer, Salivary gland cancers and more); Open Targets associates it with 0 specific cancer types at or above 0.5. (Rule 6 of scripts/fetch-target-specificity.ts.)
Sources: UniProt Q96T58; CIViC gene SPEN; IntOGen SPEN; Human Protein Atlas SPEN tissue; Open Targets ENSG00000065526 associations
First described 1999. Earliest sequence paper UniProt cites for the protein: Rhodes et al, 1999. Source.
Sources: HGNC HGNC:17575 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q96T58 (protein name, function text, keywords and locations (REST API)); CIViC gene SPEN (1 evidence items, 0 assertions, 1 variants; diseases: Diffuse Large B-cell Lymphoma (GraphQL API, CC0)); Open Targets ENSG00000065526 (association with cancer (MONDO_0004992) 0.73; per-cancer scores at or above 0.5: colorectal cancer 0.51, melanoma 0.56, acute lymphoblastic leukaemia 0.52, non-Hodgkin lymphoma 0.57, skin cancer 0.56, breast cancer 0.53 (GraphQL API, CC0)); IntOGen SPEN (driver in 20 cohorts (Act 1, LoF 18); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
May serve as a nuclear matrix platform that organises and integrates transcriptional responses. In osteoblasts, supports transcription activation: synergises with RUNX2 to enhance FGFR2-mediated activation of the osteocalcin FGF-responsive element (OCFRE). Has also been shown to be an essential corepressor protein, which probably regulates different key pathways such as the Notch pathway. Negative regulator of the Notch pathway via its interaction with RBPSUH, which prevents the association between NOTCH1 and RBPSUH, and therefore suppresses the transactivation activity of Notch signalling. Blocks the differentiation of precursor B-cells into marginal zone B-cells. Probably represses transcription via the recruitment of large complexes containing histone deacetylase proteins. Location: Nucleus (UniProt). Locus 1p36.21-p36.13 (HGNC).
RNA: low tissue specificity, detected in all normal tissues.
Medium: Adipose tissue, Breast, Duodenum, Endometrium, Fallopian tube, Liver, Lymph node, Ovary.
Medium only: lymphoma.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"SPEN" OR ABSTRACT:"SPEN" OR TITLE:"spen family transcriptional repressor" OR ABSTRACT:"spen family transcriptional repressor" OR TITLE:"Msx2-interacting protein" OR ABSTRACT:"Msx2-interacting protein" OR TITLE:"KIAA0929" OR ABSTRACT:"KIAA0929" OR TITLE:"SHARP" OR ABSTRACT:"SHARP" OR TITLE:"RBM15C" OR ABSTRACT:"RBM15C") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about SPEN, not a curated reading list.
Shares Nasopharyngeal carcinoma, Skin cancer (all types), Cervical cancer, CIViC.
Shares Nasopharyngeal carcinoma, Skin cancer (all types), IntOGen, Breast cancer (all types).
Shares Nasopharyngeal carcinoma, Renal cell carcinoma, IntOGen, Breast cancer (all types).
Shares Nasopharyngeal carcinoma, Cervical cancer, CIViC, IntOGen.
Shares Nasopharyngeal carcinoma, Renal cell carcinoma, Skin cancer (all types), CIViC.
Shares Nasopharyngeal carcinoma, Skin cancer (all types), IntOGen, Open Targets Platform.
Shares Salivary gland cancers, Renal cell carcinoma, Skin cancer (all types), IntOGen.
Shares Salivary gland cancers, CIViC, IntOGen, Breast cancer (all types).